The nucleotide supplementation experiments fully demonstrated that UCA1 affected the metabolites IMP, GMP, and GTP levels simultaneously and that GTP supplementation alone did not reverse the tumor cell phenotype. The gene discussed is UCA1; the disease is neoplasm.